Survival of Patients with Malignant Pleural Effusion: A Single Center Study
(Survival of Patients with Malignant Pleural Effusion: A Single Center Study)
| Title | Survival of Patients with Malignant Pleural Effusion: A Single Center Study |
|---|---|
| Title Original | Survival of Patients with Malignant Pleural Effusion: A Single Center Study |
| Author | Mohammad Javad Fallahi, Alireza Rezvani, Zainab Al-Saif |
| Publication Place | - Shiraz University of Medical Sciences |
| Subject | Pleural effusions, Survival |
| Type | Periodical |
| Language | Arabic |
| Digital | Yes |
| Manuscript | No |
| Library: | Bibliotecas UMA - Universidad de Málaga |
| Library Asset ID | EISSN: 2322-4339, DOI: 10.30476/smsj.2023.95854.1354 |
| Record ID | cdi_doaj_primary_oai_doaj_org_article_ea74ee8bfe754a35aed51313fc821cc2 |
| Library Location | Available Online |
| Notes | Malignant pleural effusion is one of the most common complications of advanced malignancies, leading to decreased quality of life and life expectancy. With the advent of new therapies, patients with malignant pleural effusion appear to be living longer than previously thought. In this cohort study,26 patients, with malignant pleural effusion at the initial diagnosis of primary cancer, who were referred to the Lung Cancer Clinic of Shahid Motahari Clinic affiliated with Shiraz University of Medical Sciences , were studied Information on age, sex, tumor type, mortality, survival rate after malignant pleural effusion, EGFR mutation (in lung cancer patients), and metastasis were evaluated. In the present study, 12 patients (46.2%) were male and 14 patients (53.8%) were female. The median survival of patients was 2 years (interquartile range 1-3 years). Five patients (19.2%) had breast cancer, 19 patients (77.1%) had lung cancer, and two patients (7.7%) had lymphoma. The highest survival after diagnosis was related to one of the lymphoma patients (five years). In lung and breast cancer patients, the median survival was two years (interquartile range 1.5, 3) and one year (interquartile range 1, 2.5), respectively. Although the present study was a small single-center study, due to the appropriate lifespan of malignant pleural effusion patients with new therapies, more comprehensive studies are needed to re-evaluate the survival of patients with malignant pleural effusion. |
| Sample Text | Sadra medical sciences journal, 1401-04, Vol.10 (3), p.311-316 |
Other Editions
11
Survival of Patients with Malignant Pleural Effusion: A Single Center Study
Record ID: 4689690
Survival of Patients with Malignant Pleural Effusion: A Single Center Study
Record ID: 4692298
Survival of Patients with Malignant Pleural Effusion: A Single Center Study
Record ID: 4858198
Survival of Patients with Malignant Pleural Effusion: A Single Center Study
Record ID: 5227779
Survival of Patients with Malignant Pleural Effusion: A Single Center Study
Record ID: 5300839
Survival of Patients with Malignant Pleural Effusion: A Single Center Study
Record ID: 5302197
Survival of Patients with Malignant Pleural Effusion: A Single Center Study
Record ID: 5302551
Survival of Patients with Malignant Pleural Effusion: A Single Center Study
Record ID: 5303640
Survival of Patients with Malignant Pleural Effusion: A Single Center Study
Record ID: 5304432
Survival of Patients with Malignant Pleural Effusion: A Single Center Study
Record ID: 5313975
Survival of Patients with Malignant Pleural Effusion: A Single Center Study
Record ID: 5334774